Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis - PubMed (original) (raw)
Review
Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis
Tarig Bashir et al. Adv Cancer Res. 2003.
Abstract
The ubiquitin pathway plays a central role in the regulation of cell growth and cell proliferation by controlling the abundance of key cell cycle proteins. Increasing evidence indicates that unscheduled proteolysis of many cell cycle regulators contributes significantly to tumorigenesis and is indeed found in many types of human cancers. Aberrant proteolysis with oncogenic potential is elicited by two major mechanisms: defective degradation of positive cell cycle regulators (i.e., proto-oncoproteins) and enhanced degradation of negative cell cycle regulators (i.e., tumor suppressor proteins). In many cases, increased protein stability is a result of mutations in the substrate that prevent the recognition of the protein by the ubiquitin-mediated degradation machinery. Alternatively, the specific recognition proteins mediating ubiquitination (ubiquitin ligases) are not expressed or harbor mutations rendering them inactive. In contrast, the overexpression of a ubiquitin ligase may result in the enhanced degradation of a negative cell cycle regulator. This chapter aims to review the involvement of the ubiquitin pathway in the scheduled destruction of some important cell cycle regulators and to discuss the implications of their aberrant degradation for the development of cancer.
Similar articles
- [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF, Lacombe F, Belloc F, Pellegrin JL, Reiffers J. Viallard JF, et al. Cancer Radiother. 2001 Apr;5(2):109-29. doi: 10.1016/s1278-3218(01)00087-7. Cancer Radiother. 2001. PMID: 11355576 Review. French. - The Involvement of Ubiquitination Machinery in Cell Cycle Regulation and Cancer Progression.
Zou T, Lin Z. Zou T, et al. Int J Mol Sci. 2021 May 27;22(11):5754. doi: 10.3390/ijms22115754. Int J Mol Sci. 2021. PMID: 34072267 Free PMC article. Review. - The ubiquitin-proteasome system and cancer.
Devoy A, Soane T, Welchman R, Mayer RJ. Devoy A, et al. Essays Biochem. 2005;41:187-203. doi: 10.1042/EB0410187. Essays Biochem. 2005. PMID: 16250906 Review. - SCF(Fbxw7/hCdc4) targets cyclin E2 for ubiquitin-dependent proteolysis.
Klotz K, Cepeda D, Tan Y, Sun D, Sangfelt O, Spruck C. Klotz K, et al. Exp Cell Res. 2009 Jul 1;315(11):1832-9. doi: 10.1016/j.yexcr.2008.11.017. Epub 2008 Dec 3. Exp Cell Res. 2009. PMID: 19084516 - Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta.
Ravitz MJ, Wenner CE. Ravitz MJ, et al. Adv Cancer Res. 1997;71:165-207. doi: 10.1016/s0065-230x(08)60099-8. Adv Cancer Res. 1997. PMID: 9111866 Review.
Cited by
- Validating HMMR Expression and Its Prognostic Significance in Lung Adenocarcinoma Based on Data Mining and Bioinformatics Methods.
Li X, Zuo H, Zhang L, Sun Q, Xin Y, Zhang L. Li X, et al. Front Oncol. 2021 Aug 30;11:720302. doi: 10.3389/fonc.2021.720302. eCollection 2021. Front Oncol. 2021. PMID: 34527588 Free PMC article. - Small Molecule Cjoc42 Improves Chemo-Sensitivity and Increases Levels of Tumor Suppressor Proteins in Hepatoblastoma Cells and in Mice by Inhibiting Oncogene Gankyrin.
D'Souza AM, Cast A, Kumbaji M, Rivas M, Gulati R, Johnston M, Smithrud D, Geller J, Timchenko N. D'Souza AM, et al. Front Pharmacol. 2021 Mar 4;12:580722. doi: 10.3389/fphar.2021.580722. eCollection 2021. Front Pharmacol. 2021. PMID: 33746747 Free PMC article. - Identification and Verification of Molecular Subtypes with Enhanced Immune Infiltration Based on m6A Regulators in Cutaneous Melanoma.
Lin Y, Wang S, Liu S, Lv S, Wang H, Li F. Lin Y, et al. Biomed Res Int. 2021 Jan 2;2021:2769689. doi: 10.1155/2021/2769689. eCollection 2021. Biomed Res Int. 2021. PMID: 33490266 Free PMC article. - Expression of ubiquitin-conjugating enzyme E2T in colorectal cancers and clinical implications.
Wu X, Liu G, Liu R, He J, Wang G, Zhang H, Liu T, Bai J, Cheng N, Qiu J. Wu X, et al. Oncol Lett. 2020 Nov;20(5):275. doi: 10.3892/ol.2020.12138. Epub 2020 Sep 21. Oncol Lett. 2020. PMID: 33014154 Free PMC article. - TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma.
Rusinek D, Pfeifer A, Cieslicka M, Kowalska M, Pawlaczek A, Krajewska J, Szpak-Ulczok S, Tyszkiewicz T, Halczok M, Czarniecka A, Zembala-Nozynska E, Chekan M, Lamch R, Handkiewicz-Junak D, Ledwon A, Paliczka-Cieslik E, Kropinska A, Jarzab B, Oczko-Wojciechowska M. Rusinek D, et al. Cancers (Basel). 2020 Jun 17;12(6):1597. doi: 10.3390/cancers12061597. Cancers (Basel). 2020. PMID: 32560331 Free PMC article.